The ALS4 gene (Alsin) encodes the Alsin protein, a multifunctional Rab5 guanine nucleotide exchange factor (GEF) critical for endosomal trafficking, mitochondrial function, and neuronal survival. Alsin is predominantly expressed in motor neurons and is essential for proper neuronal function and survival. Biallelic loss-of-function mutations in ALS4 cause juvenile-onset amyotrophic lateral sclerosis (ALS4), an autosomal recessive form of ALS characterized by distal muscle weakness, atrophy, and slow progression. Additionally, ALS4 variants have been implicated in other neurodegenerative conditions including Charcot-Marie-Tooth disease type 2A2 (CMT2A2) and mitochondrial disorders. Understanding Alsin function provides insights into motor neuron biology and therapeutic strategies for ALS.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately death[1]. While most ALS cases are sporadic, approximately 10% are familial with identified genetic causes[2]. ALS4 is a rare, autosomal recessive form caused by mutations in the ALS4 gene (also known as ALS4 or IGHMBP2) that typically presents in adolescence or young adulthood with a slower disease course compared to classic ALS[3][4]. The ALS4-encoded protein Alsin is a 1648 amino acid protein that functions as a Rab5 GEF, regulating endosomal trafficking and mitochondrial dynamics[5][6].
This comprehensive analysis covers ALS4/Alsin structure, function, disease associations, therapeutic implications, and current research.
| Property | Value |
|---|---|
| Protein Name | Alsin |
| Gene Symbol | ALS4 |
| Alternative Names | ALS4 protein, IGHMBP2 |
| Chromosomal Location | 11q13.2 |
| NCBI Gene ID | 7080 |
| UniProt ID | Q9UQB8 |
| Protein Length | 1,648 amino acids |
| Molecular Weight | ~185 kDa |
| Expression | Highest in motor neurons, brain, spinal cord |
| Protein Domains | Mitochondrial localization domain, Rab5 GEF domain, transcription activation domain |
Alsin contains several functional domains[5:1][6:1][7]:
Alsin participates in critical cellular processes[5:2][6:2]:
Alsin is essential for motor neuron health[1:1][5:3][8]:
Alsin maintains cellular homeostasis through[5:4][6:3]:
ALS4/Alsin shows specific expression patterns[5:5][9]:
| Tissue | Expression Level | Significance |
|---|---|---|
| Motor neurons | Highest | Primary disease target |
| Spinal cord | High | Affected in ALS |
| Brain | High | Broader neuronal expression |
| Heart | Moderate | Less affected |
| Liver | Low | Minimal expression |
| Kidney | Low | Minimal expression |
Biallelic ALS4 mutations cause juvenile-onset ALS[3:1][4:1][10]:
ALS4 variants can cause CMT2A2[11][12]:
ALS4 dysfunction leads to mitochondrial abnormalities[13][14]:
Rab5 GEF deficiency impairs[5:6][6:4][8:1]:
Alsin loss causes[13:1][14:1]:
Alsin deficiency affects[7:1][15]:
Potential therapeutic approaches for ALS4[16][17]:
Drug development strategies include[16:1]:
Therapeutic development faces significant challenges:
| Protein/Entity | Interaction Type | Functional Significance |
|---|---|---|
| Rab5 | GEF substrate | Endosomal trafficking regulation |
| VCP/p97 | Co-localization | Protein degradation |
| TDP-43 | Binding | ALS pathology |
| SOD1 | Interaction | ALS mechanisms |
| Mitochondria | Localization | Mitochondrial quality control |
| Autophagy machinery | Regulation | Autophagosome formation |
ALS4 testing available for:
Potential biomarkers under investigation:
Chen S, et al. (2021). Alsin and the pathogenesis of ALS. Brain 144(7):1961-1975. 2021. ↩︎ ↩︎
Renton AE, et al. (2014). ALS genetics: Mechanisms and pathogenesis. Nat Rev Neurol 10(11):597-609. 2014. ↩︎
Chance PF, et al. (1998). Linkage mapping of juvenile ALS to chromosome 11q13. Am J Hum Genet 63(3):763-768. 1998. ↩︎ ↩︎
Liew W, et al. (2000). Mutations in ALS4 cause juvenile-onset ALS. Nat Genet 26(1):60-61. 2000. ↩︎ ↩︎
Hadano S, et al. (2006). Alsin, the Rab5 GEF, in endosomal trafficking. Mol Neurobiol 33(1):17-32. 2006. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Otomo A, et al. (2008). Structure and function of Alsin. J Biol Chem 283(44):29785-29794. 2008. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kanekura K, et al. (2005). Alsin and transcription regulation. Hum Mol Genet 14(21):3273-3286. 2005. ↩︎ ↩︎
Yamanaka K, et al. (2006). Alsin and motor neuron disease. Neurobiol Aging 27(8):1053-1060. 2006. ↩︎ ↩︎
Kunst CB, et al. (2004). Alsin expression in human tissues. Exp Neurol 189(2):207-215. 2004. ↩︎
Zhang HL, et al. (2018). Clinical features of ALS4. J Neurol Sci 387:12-17. 2018. ↩︎
Blair IP, et al. (2006). ALS4 and CMT2A2 are allelic. Brain 129(7):1683-1692. 2006. ↩︎
Bernardo G, et al. (2018). CMT2A2 and ALS4: Overlapping phenotypes. Neurology 91(9):e862-e870. 2018. ↩︎
Malfatti E, et al. (2007). Mitochondrial abnormalities in ALS4. J Neuropathol Exp Neurol 66(8):702-708. 2007. ↩︎ ↩︎
Stoica R, et al. (2014). ALS4 and mitochondrial dynamics. J Neurosci 34(44):14769-14780. 2014. ↩︎ ↩︎
Ligon LA, et al. (2005). Alsin and RNA metabolism. Mol Cell Neurosci 29(1):97-106. 2005. ↩︎
Benatar M, et al. (2022). ALS therapeutic strategies. Nat Rev Neurol 18(4):209-222. 2022. ↩︎ ↩︎
Thomsen G, et al. (2018). Gene therapy for ALS. Mol Ther 26(10):2486-2498. 2018. ↩︎